{"filing":{"accession_number":"0001790340-26-000074","cik":"0001790340","ticker":"IMRX","company_name":"Immuneering Corp","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"imrx-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000074/imrx-20260611.htm"},"events":[{"id":11040,"run_id":9678,"accession_number":"0001790340-26-000074","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026, succeeding Mallory Morales in the principal financial officer role. While the disclosure also includes compensatory arrangements (base salary of $530,000, 40% target bonus, and 650,000 option grant), the principal disclosed action is the appointment of a named executive officer to a key financial leadership position. This is material to investors as CFO changes affect financial oversight and strategy.","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7524,"accession_number":"0001790340-26-000074","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026, succeeding Mallory Morales in the principal financial officer role. While the disclosure also includes compensatory arrangements (base salary of $530,000, 40% target bonus, and 650,000 option grant), the principal disclosed action is the appointment of a named executive officer to a key financial leadership position. This is material to investors as CFO changes affect financial oversight and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:13:16.165278+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7524,"accession_number":"0001790340-26-000074","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026, succeeding Mallory Morales in the principal financial officer role. While the disclosure also includes compensatory arrangements (base salary of $530,000, 40% target bonus, and 650,000 option grant), the principal disclosed action is the appointment of a named executive officer to a key financial leadership position. This is material to investors as CFO changes affect financial oversight and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T20:13:16.165278+00:00","company_name":"Immuneering Corp","ticker":"IMRX","filing_date":"2026-06-15"}]}